The pathogenesis of juvenile dermatomyositis (JDM) is complex and various evidence implicate a role for type I interferons. Could the use of a bioengineered paediatric skeletal muscle model provide insight into this disease and have potential for high throughput testing of therapeutic agents?
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Papadopoulou, C., Chew, C., Wilkinson, M. G. L., McCann, L. & Wedderburn, L. R. Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care. Nat. Rev. Rheumatol. 19, 343–362 (2023).
Kim, H. Updates on interferon in juvenile dermatomyositis: pathogenesis and therapy. Curr. Opin. Rheumatol. 33, 371–377 (2021).
Covert, L. T. et al. Effect of type I interferon on engineered pediatric skeletal muscle: a promising model for juvenile dermatomyositis. Rheumatology (Oxford) https://doi.org/10.1093/rheumatology/kead186 (2023).
Preusse, C. et al. Differential roles of hypoxia and innate immunity in juvenile and adult dermatomyositis. Acta Neuropathol. Commun. 4, 45 (2016).
Bolko, L. et al. The role of interferons type I, II and III in myositis: a review. Brain Pathol. 31, e12955 (2021).
Ladislau, L. et al. JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. Brain 141, 1609–1621 (2018).
Gallay, L. et al. Involvement of type I interferon signaling in muscle stem cell proliferation during dermatomyositis. Neurology 98, e2108–e2119 (2022).
Wang, J. et al. Engineered skeletal muscles for disease modeling and drug discovery. Biomaterials 221, 119416 (2019).
Bersini, S. et al. Engineering an environment for the study of fibrosis: a 3d human muscle model with endothelium specificity and endomysium. Cell Rep. 25, 3858–3868 (2018).
Kinder, T. B., Dranchak, P. K. & Inglese, J. High-throughput screening to identify inhibitors of the type i interferon-major histocompatibility complex class i pathway in skeletal muscle. ACS Chem. Biol. 15, 1974–1986 (2020).
This work was supported by the Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (project AR041215-02). The author thanks R. A. Colbert, I. Pinal-Fernandez, L. G. Rider and A. Schiffenbauer for their critical reading and input.
H.K. is part of a clinical study at NIAMS that received grant support for under a government CRADA from Eli Lilly.
About this article
Cite this article
Kim, H. Insights into juvenile myositis via engineered muscle. Nat Rev Rheumatol 19, 543–544 (2023). https://doi.org/10.1038/s41584-023-01003-6